Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQZ-eAPC-HPV in HPV16+ Solid Tumors
NCT05357898Phase 2Terminated
- Sponsor
- SQZ Biotechnologies
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SQZ-eAPC-HPV in solid tumor, head and neck cancer (HNC), Cervical Cancer (CC), anal cancer, vulvar cancer, sponsored by SQZ Biotechnologies. Started Mar 2022; status: terminated.
02
Drugs
SQZ-eAPC-HPV
03
Conditions
solid tumorhead and neck cancer (HNC)Cervical Cancer (CC)anal cancervulvar cancer
Beyond the preview
Go deeper on NCT05357898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357898.